Latest filingSep 01, 2026Most recent Form 4
GRCE
Grace Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$2.42M1 buys
Total selling$00 sells
Net open-market+$2.42M4 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period4transactions
- A · Grants / awards · dominant3 · 75%
- P · Open-market buys1 · 25%
Activity by reported role
A joint filing can contribute to multiple roles4transactions
- 10% owner · dominant1 · 25%
- Chief executive officer1 · 25%
- CMO1 · 25%
- VPM1 · 25%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (4)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeOpaleye Management Inc.Common Stock, par value $0.0001 per share · Indirect · By Opaleye, L.P.
2,760,000Aug 14, 2026
Macdonald R. LochStock Option (Right to Buy) · Direct
54,690Aug 28, 2026
Kohli PrashantStock Option (Right to Buy) · Direct
267,160Aug 28, 2026
Kumar AmreshStock Option (Right to Buy) · Direct
35,760Aug 28, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
GRCE transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
No transactions match your filtersOnce the backend ingests and parses SEC filings, they will appear here. Try removing a filter or picking a wider date range. | ||||||||||
Grace Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Grace Therapeutics, Inc.?
Kumar Amresh, Kohli Prashant, Macdonald R. Loch, Opaleye Management Inc..
When was the latest reported open-market purchase?
Opaleye Management Inc. reported a buy on Aug 14, 2026 valued at $2.42M. Read the SEC filing.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $24,206.16. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.